In an effort to better position itself as a leader in the health and nutritional products arena, Atrium Innovations is considering a sale of its active ingredients and specialty chemicals division, the Canadian nutritional products marketer announces Dec. 18. A sale of the division would "strengthen Atrium with a targeted vision and development strategy in the high potential nutritional supplements market," the Quebec-based firm says, noting it plans to act as a consolidator in the fragmented segment. Atrium strengthened its health division with the purchase of German-based Mucos in July and was recently granted permission to sell Mucos' enzyme-based supplement Wobenzym N in the U.S. (1"The Tan Sheet" Nov. 26, 2007, In Brief)...

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February.